Case Report

Stiff-person syndrome with paraneoplastic neurological syndrome: a case report and literature review

Hanwen Zhang*, Wenshi Wei*

Department of Neurology, Huadong Hospital Affiliated to Fudan University, No. 221, West Yan An Road, Shanghai, China. * Equal contributors.

Received October 11, 2021; Accepted January 18, 2022; Epub February 15, 2022; Published February 28, 2022

Abstract: Background: Stiff-person syndrome (SPS) manifests by progressive rigidity along with muscle spasms that affect the axial and limb muscles. First discovered in 1956, significant progress has been made in its clinical characterization, comprehension of pathogenesis, as well as effective treatment therapy. Case presentation: A 67-year-old female patient presented with a 2-year history of progressive stiffness along with painful spasms in both legs, with her condition worsening over the previous year making it considerably difficult for her to stand and walk. Here, we report a Stiff-person syndrome patient (SPS) with lung adenocarcinoma who was positive for anti-glutamate decarboxylase (anti-GAD) antibodies. Treatment with hormones and gamma-globulin improved her symptoms. In addition, we present a literature review of SPS patients with tumors. Conclusions: The diagnosis of autoimmune SPS was on the basis of clinical, electrophysiological, as well as immunological findings. Early SPS detection is critical to preventing long-term disability.

Keywords: Muscle stiffness, stiff person syndrome, rigidity, anti-glycine receptor antibody, paraneoplastic neurological syndrome, lung adenocarcinoma

Introduction

Stiff-person syndrome (SPS) is a rarely disabling central nervous system disorder that manifests with muscle stiffness, rigidity, and episodic painful spasms of the proximal and axial limb muscles. Circulating anti-GAD65 (glutamic acid decarboxylase) antibodies are characteristic of the disorder and exhibit distinct epitope specificity, potentially inhibiting glutamate decarboxylase and GABA synthesis. GABA is the primary suppressive neurotransmitter in the brain and reduced GABA levels may cause muscle hyperfunction [1]. Some cases of paraneoplastic SPS occur in association with antiamphiphysin antibodies. In paratumor SPS, the cross-reactive binding of serum antibodies to malignant cells expressing neuronal antigens (e.g. GAD and amphoteric fibrin) may trigger an autoimmune response. Although SPS research has made great progress in recent years, due to its variable clinical manifestations the workload of differential diagnosis is large, increasing misdiagnosis. Additionally, SPS is sometimes accompanied by tumors, including thymoma [2, 3], Hodgkin’s lymphoma [4-6], small cell lung cancer [6, 7], and breast cancer [8]. Herein, we report a case of GAD antibody-positive SPS associated with lung adenocarcinoma.

Case report

This SPS case report involves a 67-year-old female patient who was admitted to our hospital’s neurology clinic with the complaint of painful muscle contractions in 2018. She had experienced sudden, occasional pain in both heels for about 2 years, before the pain spread upwards. Symptoms first appeared in 2016, with a one-year history of irregular right lower limb stiffness that the patient described as ‘painful spasms’, resulting in poor sleep at night. She experienced reflex contraction of the muscles of the right lower limb, with the right foot held in plantar flexion. She then began walking unsteadily and was unable to turn over independently, leading to admission at another
hospital. Except for muscle stiffness, there was no obvious numbness or weakness in lower limbs. The rest of her neurological assessment was normal. The patient had no medical or medication history for the condition. She felt stiff from the groin to feet. During that time, spasm and spasticity of her lower limbs gradually deteriorated, making it considerably difficult for her to stand and walk. The patient denied having any trauma, infection, poisoning, drugs, mental illness, and family history of the condition. Due to misdiagnosis as osteoporosis and Parkinson’s disease, the patient was initially treated with glucosamine, sulfate, elcatonin, celebrex, levodopa, and gabapentin but these were ineffective. Within the year prior to the initial hospital visit, she had fallen down several times due to muscle spasms. The main focus during the patient’s visit was SPS, which she reported was exacerbated by tension beyond her control and vice versa. Upon examination, her pulse rate, oxygen saturation, blood pressure, temperature and respiratory rate, and were 78 beats/min, 100%, 145/83 mmHg, 36.8°C, and 18 breaths/min, respectively. Her breath sounds were clear on chest auscultation. Her painful spasms included lumbar stiffness due to agonist and antagonist muscle contractions and high lumbar hyperactivity. During neurological examination, her lower limb strength was measured by manual muscle test (MMT) of 4/5, with severe spasms and hyper-reflexes.

Babinski and Chaddock’s reflexes were hard to assess due to spasms. The patient had no sensory disturbances. Initial laboratory examinations revealed: white blood cell count = 4,700/mm³; hemoglobin = 11.9 mg/dL, potassium = 4.0 mEq/L, platelet count = 23.4×10⁳, C-reactive protein = 0.8 mg/dL, ALT (alanine aminotransferase) = 14 IU/L, lactate dehydrogenase = 180.3 IU/L, creatine = 50.4 umol/L, uric acid = 260 umol/L, sodium = 142 mEq/L, Laspartate aminotransferase = 17 international units (IU)/L, chloride = 104.9 mEq/L, glucose = 4.5 mmol/L, HbA1c = 5.5%, IgA = 2.94 g/L, IgG = 13.69 g/L, IgM = 0.84 g/L, prothrombin time = 11.7 sec, INR = 1.01 (normal INR = 1-2, activated partial thromboplastin time = 27.3 sec, and vitamin B12 = 815 pg/mL. The exception was positive anti-GAD antibodies in serum titers at 1:10. Spinal MRI findings were normal. Electromyography (EMG) evaluation showed continuous motor unit activity in both agonist and antagonist muscles. Electroencephalography (EEG) revealed no epileptic discharge. Brain MRI (magnetic resonance imaging) was normal. Cancer screening tests were all negative. Based on the medical history and auxiliary examination results, the patient was diagnosed with SPS based on clinical SPS diagnosis criteria by Dalakas et al.

Based on clinical history and the significant muscle spasms with stimulation, 0.5 mg clonazepam, twice daily, was added to her medication regimen. In the next days, the patient reported that clonazepam reduced stiffness onset. The patient also received intravenous immune globulin (10 g/day) for 3 days. Upon clonazepam dose increase to 3 times daily, she reported reduced frequency of anxiety-triggered spasms and less stiffness. During her first hospitalization a CT scan of the thorax revealed a 1.0-cm mass in the left inferior lobe anterior segment. Chest CT scan revealed ground-glass opacities, but the patient refused further PET-CT scan due to cost and improved symptoms.

After discharge, the patient remained on 1 mg oral clonazepine before bed. During follow-up, compatible with the last CT results, a CT scan done in July 2020 revealed a ground glass nodule in the lungs suspicious for early adenocarcinoma (Figure 1). The patient underwent left inferior lobectomy in August 2020 with patho-
logical result revealing a well-differentiated adenocarcinoma with bronchoalveolar features (Figure 2). A molecular evaluation of genetic changes in EGFR (exon 21, 20, 19, and 18), ROS-1 and ALK genes. PD-L1 immunohistochemistry (ICH) analysis of the primary tumor as a new biopsy was not feasible technically. Rare complex EGFR mutations (exon 20 V769M and exon 18 G719A) were detected by PCR-based Sanger sequencing. No alterations were reported as EGFR, ROS-1 ICH and DAKO ALK were all negative. Similarly, DAKO PDL-1 ICH 22 C3 was negative (Tumor proportion score 0%). The patient’s symptoms markedly improved in December 2020.

Discussion

SPS is an uncommon neurological autoimmune disorder that manifests with stiffness, rigidity along with spontaneous reflex- or action-triggered painful spasms in axial and proximal limb muscles. Initially reported in 1956 by Moersch and Woltman who described fourteen patients with fluctuating, but progressive rigidity along with painful-muscle spasms, causing gait difficulties, falls, and a ‘wooden-man’ appearance, hence the term ‘stiff man syndrome’. SPS prevalence is unknown but its incidence is estimated at about 1 in 1,000,000 individuals in both genders although it predominantly affects females [9]. SPS symptoms become apparent at 30-60 years of age [10]. SPS is clinically diagnosed based on high suspicion. Although this case did not meet the 2 minor criteria, SPS was diagnosed based on the main clinical manifestations and clear continuous motor activity of the agonist along with antagonist muscles on EMG [11]. SPS diagnosis is on the basis of the following clinical criteria: 1) muscular rigidity in the limbs, as well as the axial (trunk) muscles, dominant in the thoracolumbar and abdominal paraspinals, 2) persistent co-contraction of agonist, as well as antagonist muscles, verified electrophysiologically and clinically, 3) positive anti-GAD65 (glutamic acid decarboxylase-65, or amphiphysin) antibodies as per radioimmunoassay, immunocytochemistry, or western blot, 4) absence of any other neurologic disease to account for the rigidity and stiffness, and 5) episodes of spasms caused by unexpected noise, emotional upset, or tactile stimuli [12]. Clinical assessment reveals rigidity of the limbs with no extrapyramidal or pyramidal tract manifestations. SPS is often linked to other autoimmune diseases, as well as autoantibodies. In 5% of the patients, SPS has a paraneoplastic symptom. Such patients might have more pronounced stiffness in the arms and neck [1]. Diagnosis errors are common, including misdiagnosis as Parkinson’s disease, multiple sclerosis, or primary lateral sclerosis.

However, few cases of SPS patient with early lung cancer characterized by lung GGO change are known. Clinical SPS diagnosis strongly relies on understanding the major clinical manifestations of rigidity, as well as normal motor unit potential (MUPs), typical EMG (EMG), continued involuntary discharge performance, and autoantibody-positive serology. Important diagnostic basis for this disease include EMG characteristics and clinical manifestations. At rest, EMG can detect sustained normal motor unit activity, with significant increase in seizures. The disease usually begins insidiously, with intermittent muscle tension or pain, and eventually develops into increased muscle tension or rigidity associated with continuous co-contraction of the antagonistic muscle groups. This leads to limited range of motion, slow spontaneous movement, muscle hypertrophy, and characteristic lumbar anterior protrusion postures. SPS often develops from the trunk to the near end, and then to the distal limb muscles, affecting gait and balance. Patients may also experience muscle spasms due to emotional
distress, shock (triggered by tactile, visual, and auditory stimuli), or sudden contraction of neighboring muscles [13]. Five percent of SPS cases are associated with malignancies, especially neoplasms of the breast, thymus, colon, and lung, as well as Hodgkin’s lymphoma [14]. In patients presenting SMS without particular causes, general examinations, especially chest examinations, are essential for diagnosis. In this case, a chest CT scan revealed ground glass opacities in both lungs, but the patient refused further PET-CT scan and lumbar puncture. The initial anti-GAD antibodies autoantibody panel was positive. Nevertheless, we finally confirmed that the patient had evidence of paraneoplastic syndrome based on biological tests and imaging.

SPS treatment is based on symptomatic treatment of triads, immunotherapy, and cancer treatment as appropriate. Treatment involves drugs like diazepam (5-75 mg orally, 4 times a day) to enhance γ-GABAergic transmission. Baclofen, vigabatrin, sodium valproate, and gabapentin may also help treat refractory or severe cases. Intravenous immunoglobulin therapy is sometimes effective for patients [14].

By the end of treatment, the patient had significantly better mobility with resolved muscle spasms and was discharged to inpatient rehabilitation. Had the patient not responded to first-line treatment, IVIg [15] and therapeutic plasma exchange (TPE) [16] immunomodulators like rituximab were likely to be the next best steps in management. The latest evidence from case reports and case series suggests that about half of SPS patients benefit from TPE treatment. Interestingly, manifestations have been documented to improve or even disappear with cancer treatment [17]. For patients who paraneoplastic syndromes cannot be completely ruled out, regular follow ups should be used to assess their clinical state and surveillance of cancer occurrence.

Conclusion

Stiff person syndrome (SPS) ranges from mild to severe and can be disabling if untreated. Despite advances in comprehending and treating SPS, it remains underdiagnosed, delaying treatment. Thus, increased awareness of SPS among practicing physicians is necessary.

Disclosure of conflict of interest

Written consent was obtained from the patient. The authors certify that they have obtained all appropriate patient consent forms. The patient gave consent for the images and other clinical information to be reported in the journal. The patient understands that their name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Address correspondence to: Dr. Wenshi Wei, Department of Neurology, Huadong Hospital Affiliated to Fudan University, Huadong Hospital Affiliated to Fudan University, No. 221, West Yan An Road, Shanghai, China. Tel: +86-13818396027; E-mail: wenshiwei1999@163.com

References


SPS with lung adenocarcinoma


